Tivnan et al. exploited the high expression level of the tumor-associated antigen disialoganglioside (GD2) in neuroblastoma to develop GD2-targeting MSN for the delivery of miR-34 into neuroblastoma murine models [56]. Here, MSN is linked to neuroblastoma.